Hereditary Cancer Tests Menu

TEST AVAILABLE	HIGH-RISK GENES	MODERATE-RISK GENES	NEWER GENES
Brain Tumor Panel (23 genes)	*APC, CDKN2A, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, NF2, PMS2, PTCH1, PTEN, TP53, TSC1, TSC2, VHL*		*CDKN1B, DICER1, POT1, SMARCA4, SMARCB1, SMARCE1, SUFU*
BRCA1/BRCA2 Ashkenazi Founder Panel	*BRCA1, BRCA2* Three Targeted Pathogenic Variants		
BRCA1/BRCA2 Sequencing and Deletion/ Duplication Analysis	*BRCA1, BRCA2*		
Breast Cancer Management Panel (9 genes)	*BRCA1, BRCA2, CDH1, PALB2, PTEN, TP53*	*ATM, CHEK2*	*NBN*
Breast/Gyn Cancer Panel (24 genes)	*BRCA1, BRCA2, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, TP53*	*ATM, BRIP1, CHEK2, RAD51C, RAD51D*	*BARD1, FANCC, FANCM, NBN, POLD1, RECQL*
Colorectal Cancer Panel (20 genes)	*APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, TP53*	*ATM, CHEK2*	*AXIN2, NTHL1, POLD1, POLE, SCG5/GREM1*
Common Cancer Management Panel (37 genes)	*APC, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, SDHB, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL*	*ATM, BRIP1, CHEK2, RAD51C, RAD51D*	*AXIN2, NBN, NTHL1, POLD1, POLE, SCG5/ GREM1, SDHC*
Comprehensive Common Cancer Panel (47 genes)	*APC, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, EPCAM, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, SDHB, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL*	*ATM, BRIP1, CHEK2, RAD51C, RAD51D*	*AXIN2, BAP1, BARD1, CDK4, FANCC, FANCM, HOXB13, MET, MITF, NBN, NTHL1, POLD1, POLE, POT1, RECQL, SCG5/GREM1, SDHC*
Hereditary MDS/Leukemia Panel (12 genes)	*TERC, TERT, TP53*		*ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SAMD9, SAMD9L SRP72*
Hereditary Prostate Cancer Panel (16 genes)	*BRCA1, BRCA2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, TP53*	*ATM, BRIP1, CHEK2, RAD51C, RAD51D*	*HOXB13, NBN*
Lynch/Colorectal High Risk Panel (7 genes)	*APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2*		
Melanoma Panel (9 genes)	*BRCA2, CDKN2A, PTEN, RB1,TP53*		*BAP1, CDK4, MITF, POT1*
Pancreatic Cancer Panel (15 genes)	*APC, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, VHL*	*ATM*	*CDK4*
Renal Cancer Panel (18 genes)	*EPCAM, FH, FLCN, MLH1, MSH2, MSH6, PMS2, PTEN, SDHB, SDHD, TP53, TSC1, TSC2, VHL*		*BAP1, MET, MITF, SDHC*

High-Risk Genes:

- Well-studied
- Greater than 4-fold risk of developing one or more cancers
- Can cause a moderate risk for other cancers
- National or expert opinion guidelines for screening and prevention are established

Moderate-Risk Genes:

- Well-studied
- Approximately 2- to 4-fold risk of developing one or more cancers
- May increase risk for other cancers
- Limited guidelines for screening and prevention

Newer Genes:

- Not as well-studied
- Precise lifetime risks and tumor spectrum not yet determined
- Guidelines for screening and prevention are limited or not available

BioReference LABORATORIES | genpath
OPKO Health Companies

481 Edward H. Ross Drive, Elmwood Park, NJ 07407 | **T** 1 800 627 1479 | **F** 1 201 345 7166 | www.GenPath.com